Drug Topics

JANUARY 31, 2025

There is no standard way to define resilience in adolescent patients with type 1 diabetes, though many studies see resilience as an ability or process.

371

371

PharmaVoice

JANUARY 31, 2025

Despite regulatory uncertainty, pharma is bouncing back from a market slump and is being fueled by innovation.

147

147

Drug Topics

JANUARY 31, 2025

Tocilizumab-anoh is the biosimilar formulation for ACTEMRA, a medication used to treat rheumatoid arthritis, COVID-19, and other diseases.

FDA 247

FDA 247

Pharmacy Times

JANUARY 31, 2025

The approval includes indications for rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19.

FDA 127

FDA 127

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

JANUARY 31, 2025

Axsome Therapeutics expects the therapy to be commercially available in the United States in approximately 4 months.

FDA 247

FDA 247

Fierce Healthcare

JANUARY 31, 2025

The increase, meant to offset and exceed a 2.8% pay cut that began in January, would likely need to find its way into a funding bill Congress must pass in March.

124

124

Fierce Healthcare

JANUARY 31, 2025

To help prevent painful injuries and costly hospitalizations, and reduce dependence on dangerous opioids, access to physical and occupational therapy services should be strengthened and sweeping payment model cutswhich only would further destabilize access to careshould be soundly rejected.

Hospitals 115

Hospitals 115

Pharmaceutical Technology

JANUARY 31, 2025

The FDA has approved Vertex Pharmaceuticals oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.

FDA 108

FDA 108

pharmaphorum

JANUARY 31, 2025

In a shock move, AstraZeneca has ditched its plan to invest 450m in a new vaccine manufacturing plant in the UK.

Vaccines 97

Vaccines 97

Pharmaceutical Technology

JANUARY 31, 2025

Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching 880m ($833m).

105

105

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

JANUARY 31, 2025

Metsera and Maze Therapeutics have become the second and third biotechs to complete an IPO on the Nasdaq this year.

95

95

Pharmaceutical Technology

JANUARY 31, 2025

Roche achieved a sales growth of 7% (3% in CHF) in 2024, citing strong demand for pharmaceutical products.

93

93

pharmaphorum

JANUARY 31, 2025

Recent financings in the digital health and AI space include rounds for Rad AI, Eleos, Allara Health, Manas AI, Delfina Care, and Grey Matter Neuro

93

93

Pharmacy Times

JANUARY 31, 2025

Expert weighs in on data from the AQUILA trial and Johnson & Johnson's approval request for daratumumab for smoldering multiple myeloma.

73

73

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

JANUARY 31, 2025

Vertex gets FDA approval for its non-opioid pain drug suzetrigine, the first new class of pain medicine in the US in more than 20 years.

FDA 80

FDA 80

Pharmacy Times

JANUARY 31, 2025

Donna Ryan, MD discusses GLP-1 medications and new developments on the horizon, while providing some best practices for patients initiating treatment, including important nutritional and lifestyle changes,

73

73

STAT

JANUARY 31, 2025

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds.  Sign up here. Too much news to include below, but apparently we should all be scratching our itches.

66

66

Pharmacy Times

JANUARY 31, 2025

The diabetes treatment landscape is rapidly evolving, with new combination therapies and oral GLP-1 medications, positioning pharmacists to have an important role in personalizing care.

73

73

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

The Checkup by Singlecare

JANUARY 31, 2025

The blockbuster GLP-1 drug Ozempic has received approval for yet another chronic medical condition. The U.S. Food and Drug Administration (FDA) expanded Ozempics indication to reduce the risk of kidney disease worsening, kidney failure, and death due to cardiovascular disease in adults with Type 2 diabetes and chronic kidney disease (CKD). Chronic kidney disease is very serious and common in patients living with Type 2 diabetes and represents a critical need for adults living with these comorbid

FDA 63

FDA 63

Pharmacy Times

JANUARY 31, 2025

The regenerative medicine advanced therapy designation expedites the development and review of regenerative medications that have the potential to address unmet needs for serious or life-threatening diseases.

FDA 65

FDA 65

Pharmaceutical Technology

JANUARY 31, 2025

The CDMO has not disclosed how many employees will be affected by the operational wind down.

59

59

Pharmacy Times

JANUARY 31, 2025

Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors have transformed the treatment of hormone receptor-positive/HER2-negative breast cancer across metastatic and early-stage settings, with ongoing research exploring their potential in additional breast cancer subtypes, combination therapies, and aggressive disease scenarios.

65

65

Pharmaceutical Commerce

JANUARY 31, 2025

Celltrions Avtozma has been indicated for the treatment of giant cell arteritis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis, systemic juvenile idiopathic arthritis, and COVID-19in the same dosages and formulations as its tocilizumab reference product.

Dosage 59

Dosage FDA 59

Pharmacy Times

JANUARY 31, 2025

The model also predicted prevalent cases of decompensated cirrhosis would more than triple, incident liver cancer cases would nearly double, and transplant almost quadruple.

65

65

Pharmaceutical Technology

JANUARY 31, 2025

On 1 January 2025, important legal amendments relating to drug pricing in Germany included in the Medical Research Act came into legal force.

59

59

Pharmacy Times

JANUARY 31, 2025

Myelofibrosis patients with CALR mutations have lower responses to symptoms and higher rates of anemia after 6 months of therapy with ruxolitinib.

65

65

Pharmaceutical Technology

JANUARY 31, 2025

CRISPR-based gene therapy Casgevy has been made available to patients with sickle cell disease in England.

59

59

The Happy PharmD

JANUARY 31, 2025

Pharmacists are at a breaking point. Once passionate about their careers, many are now feeling burnt out, overworked, and honestly, disillusioned. Its hard to ignore the signsempty shelves, frustrated staff, angry customers, and more pharmacists walking out the door every day. What happened to the job that many once loved? Pharmacists have become the healthcare systems punching bag.

Mail-Order Pharmacies 52

Mail-Order Pharmacies Insurance Patient Care Vaccines 52

Pharmaceutical Technology

JANUARY 31, 2025

The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various factors.

59

59

PharmExec

JANUARY 31, 2025

Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 hours, and reduces the need for rescue medication.

FDA 52

FDA 52

Pharmaceutical Technology

JANUARY 31, 2025

Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as chief executive officer from 1 April 2025.

59

59

PharmExec

JANUARY 31, 2025

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52

52

pharmaphorum

JANUARY 31, 2025

Watch the exclusive interview with Steve Pakola during the JP Morgan Week 2025 as he shares insights and updates on the latest trends and developments in the industry.

52

52